THE KLOW RECORD · A FOUR-PEPTIDE CATALOGUE
KLOW peptide is a four-peptide research blend with no combination study on the record.
Four peptides — KPV, GHK-Cu, BPC-157 and TB-500 — inscribed as four distinct columns of the literature, each finding cited to the constituent it belongs to, the one unwritten chapter marked plainly.
Before the details
The KLOW peptide is not one substance. It is four research peptides — KPV, GHK-Cu, BPC-157 and TB-500 — dissolved together in one vial. The four stay separate molecules; they do not fuse into a new one. Each was studied on its own, mostly in cells and animals, for a different part of healing: calming inflammation, building the skin's framework, growing new blood vessels and helping cells move to close a wound. The vial pairs them on the idea that those four jobs work together. Here is the honest part: no proper study has ever tested the four mixed together. Every claim that they add up is an educated guess from the single-peptide research, not direct proof. None of the four is FDA-approved, and the mix is sold for laboratory use only. What people report — including the downsides — is on the effects page, and you can read what the component research shows or compare KLOW vs GLOW comparison.
What is KLOW peptide?
KLOW peptide is a co-formulation — four chemically distinct research peptides supplied in a single vial at fixed mass ratios. The four are KPV (a three-amino-acid fragment of a hormone called alpha-MSH, studied for calming inflammation), GHK-Cu (a copper-carrying tripeptide studied for collagen and gene expression), BPC-157 (a 15-amino-acid peptide studied in rodent tissue repair) and TB-500 (a short fragment of the protein thymosin beta-4, studied for cell movement and wound closure). They remain four separate molecules co-dissolved together — a co-formulation, not a single compound, and not a single FDA-approved product. No pharmacopeial KLOW exists; the mixture is supplied strictly as a research-chemical co-formulation.
What the KLOW blend is
The KLOW blend is a lyophilized (freeze-dried) mixture of four peptides at a fixed ratio, most often listed as an 80 mg total vial. The design logic is that the four occupy largely non-overlapping nodes of one tissue-repair network: KPV suppresses inflammatory transcription, GHK-Cu drives matrix synthesis and supplies copper for collagen crosslinking, BPC-157 drives the angiogenic pathway, and TB-500 sequesters G-actin to support cell migration. That rationale is drawn entirely from the single-component literature. No controlled in-vivo or human study has tested the four-peptide KLOW blend against monotherapy, any subset, or placebo, so every combination claim is a mechanistic extrapolation — not direct blend evidence. This catalogue marks that gap plainly rather than reading component findings as blend efficacy.
What is in the 80 mg KLOW vial?
The most widely listed research-vial composition is an 80 mg total of GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu is the mass-dominant component at about 62.5% of the vial by mass — which is also why a reconstituted KLOW solution can read blue, since GHK-Cu carries a copper(II) ion and copper(II) complexes are characteristically blue. The four peptides remain separate molecules co-dissolved at fixed ratios. Each carries its own molecular identity: KPV (MW 342.44 Da), GHK-Cu (MW 402.92 Da), BPC-157 (MW 1419.53 Da) and TB-500 (Ac-LKKTETQ, MW 889.02 Da). There is no single CAS, UNII or PubChem identifier for the mixture, because a mixture is not a defined substance.
What does the KLOW peptide do?
By design the KLOW peptide pairs four arms of one repair network. KPV is the anti-inflammatory arm: at nanomolar concentrations it inhibits NF-kappaB (a master switch for inflammatory genes) and MAP-kinase signaling and reduces pro-inflammatory cytokine output [3]. GHK-Cu is the matrix arm: it stimulates collagen and proteoglycan synthesis and modulates a large fraction of assayed genes in fibroblasts [4][5]. BPC-157 is the tissue-repair arm: in a transected rat Achilles tendon it accelerated healing across biomechanical, functional and microscopic measures [2]. TB-500 is the cell-migration arm, carrying the actin-binding motif of thymosin beta-4, the protein whose full-length form accelerated wound re-epithelialization in rats [1]. What the combination actually does is unproven — there is no blend study.
Do the peptides in KLOW have any research on hair growth?
Two of KLOW's components carry hair-follicle research. Thymosin beta-4 — the protein the TB-500 fragment is derived from — activated hair-follicle bulge stem cells and increased hair growth in rats and mice at nanomolar concentrations, raising MMP-2 expression [6][9]. Copper-tripeptide complexes related to GHK-Cu stimulated follicle activity in C3H mice [7], and AHK-Cu, a close copper-tripeptide analog of GHK-Cu, elongated human hair follicles ex vivo and reduced dermal-papilla-cell apoptosis at picomolar-to-nanomolar concentrations [8]. This is hair-follicle research on the KLOW peptides at the component level and mostly preclinical; the KLOW blend itself has never been tested for hair growth. Read more in KLOW peptide benefits in the component research.